ID   HBL-2 [Human mantle cell lymphoma]
AC   CVCL_4216
SY   Hbl-2; HBL2
DR   BTO; BTO:0002523
DR   Cosmic; 1047112
DR   Cosmic; 2296990
DR   GEO; GSM155078
DR   GEO; GSM155079
DR   GEO; GSM155080
DR   GEO; GSM629486
DR   GEO; GSM629487
DR   GEO; GSM1266775
DR   GEO; GSM1266776
DR   Wikidata; Q54881432
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=3338018;
RX   PubMed=15028022;
RX   PubMed=16183118;
RX   PubMed=16960149;
RX   PubMed=17332242;
RX   PubMed=21746927;
RX   PubMed=24362935;
RX   PubMed=25960936;
RX   PubMed=26194763;
CC   Population: Japanese.
CC   Doubling time: 36 hours (PubMed=3338018).
CC   HLA typing: A*31:01,24:02; B*52:01,35:01; C*04:01,12:02; DQA1*03:02,01:03; DQB1*06:01,03:03; DRB1*09:01,15:02 (PubMed=25960936).
CC   Karyotypic information: Has lost chromosome Y.
CC   Omics: Array-based CGH.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Cervical lymph node; UBERON=UBERON_0002429.
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   84Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 20
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=3338018; DOI=10.1002/1097-0142(19880201)61:3<483::AID-CNCR2820610313>3.0.CO;2-L;
RA   Abe M., Nozawa Y., Wakasa H., Ohno H., Fukuhara S.;
RT   "Characterization and comparison of two newly established Epstein-Barr
RT   virus-negative lymphoma B-cell lines. Surface markers, growth
RT   characteristics, cytogenetics, and transplantability.";
RL   Cancer 61:483-490(1988).
//
RX   PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x;
RA   Kamimura K., Hojo H., Abe M.;
RT   "Characterization of expression of protein kinase C isozymes in human
RT   B-cell lymphoma: relationship between its expression and prognosis.";
RL   Pathol. Int. 54:224-230(2004).
//
RX   PubMed=16183118; DOI=10.1016/j.leukres.2005.08.016;
RA   Tucker C.A., Bebb G., Klasa R.J., Chhanabhai M., Lestou V.S.,
RA   Horsman D.E., Gascoyne R.D., Wiestner A., Masin D., Bally M.,
RA   Williams M.E.;
RT   "Four human t(11;14)(q13;q32)-containing cell lines having classic and
RT   variant features of mantle cell lymphoma.";
RL   Leuk. Res. 30:449-457(2006).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=17332242; DOI=10.1182/blood-2006-11-057208;
RA   Pinyol M., Bea S., Pla L., Ribrag V., Bosq J., Rosenwald A., Campo E.,
RA   Jares P.;
RT   "Inactivation of RB1 in mantle-cell lymphoma detected by
RT   nonsense-mediated mRNA decay pathway inhibition and microarray
RT   analysis.";
RL   Blood 109:5422-5429(2007).
//
RX   PubMed=21746927; DOI=10.1073/pnas.1018941108;
RA   Beltran E., Fresquet V., Martinez-Useros J., Richter-Larrea J.A.,
RA   Sagardoy A., Sesma I., Almada L.L., Montes-Moreno S., Siebert R.,
RA   Gesk S., Calasanz M.J., Malumbres R., Rieger M., Prosper F.,
RA   Lossos I.S., Piris M.A., Fernandez-Zapico M.E.,
RA   Martinez-Climent J.A.;
RT   "A cyclin-D1 interaction with BAX underlies its oncogenic role and
RT   potential as a therapeutic target in mantle cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:12461-12466(2011).
//
RX   PubMed=24362935; DOI=10.1038/nm.3435;
RA   Rahal R., Frick M., Romero R., Korn J.M., Kridel R., Chan F.C.,
RA   Meissner B., Bhang H.-E.C., Ruddy D., Kauffmann A., Farsidjani A.,
RA   Derti A., Rakiec D., Naylor T., Pfister E., Kovats S., Kim S.,
RA   Dietze K., Dorken B., Steidl C., Tzankov A., Hummel M., Monahan J.,
RA   Morrissey M.P., Fritsch C., Sellers W.R., Cooke V.G., Gascoyne R.D.,
RA   Lenz G., Stegmeier F.;
RT   "Pharmacological and genomic profiling identifies NF-kappaB-targeted
RT   treatment strategies for mantle cell lymphoma.";
RL   Nat. Med. 20:87-92(2014).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26194763; DOI=10.1182/blood-2015-01-624585;
RA   Bhatt S., Matthews J., Parvin S., Sarosiek K.A., Zhao D.-K., Jiang X.-Y.,
RA   Isik E., Letai A.G., Lossos I.S.;
RT   "Direct and immune-mediated cytotoxicity of interleukin-21 contributes
RT   to antitumor effects in mantle cell lymphoma.";
RL   Blood 126:1555-1564(2015).
//